Amkor Q2 Earnings: Record Quarter, Mixed Guidance

Amkor Q2 Earnings showed record second-quarter revenue and an EPS beat while Q3 guidance was framed as mixed, complicating near-term trader positioning.

July 27, 2026·2 min read
View all news articles
Flat vector package substrate with split finish symbolizing Amkor Q2 Earnings mixed guidance on a violet-mist gradient.

KEY TAKEAWAYS

  • Reported record Q2 revenue of $1.90 billion and diluted EPS of $0.70, beating Street estimates.
  • Guided Q3 net sales $1.95 billion to $2.05 billion while raising margin and EPS targets.
  • Set full-year capex at about $2.5 billion to $3.0 billion, signaling continued investment.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Amkor Technology, in its Amkor Q2 earnings release on July 27, 2026, reported record second-quarter revenue and an EPS beat, while third-quarter guidance was widely framed as mixed even as management raised margin and EPS targets.

Record Second-Quarter Results

Amkor Technology reported net sales of $1.90 billion for the second quarter of 2026, up 26% year over year and 13% sequentially, marking a record quarter. The company posted net income of $174 million and diluted earnings per share of $0.70. Gross profit was $319 million, operating income $200 million, and EBITDA $400 million.

Management highlighted record revenue in the Computing and Automotive & Industrial end markets. The results exceeded consensus estimates, which ranged from $1.81 billion to $1.82 billion in revenue and $0.47 to $0.48 in EPS.

The company confirmed these figures in a press release titled "Amkor Technology Reports Financial Results for the Second Quarter 2026" and a Form 8-K filing with the SEC.

Mixed Guidance and Capital Plan

For the third quarter of 2026, Amkor forecast net sales between $1.95 billion and $2.05 billion, gross margin of 18.5% to 19.5%, net income of $180 million to $205 million, and diluted EPS of $0.72 to $0.82. Full-year capital expenditures were set at approximately $2.5 billion to $3.0 billion.

Although the revenue guidance is higher than the second quarter’s sales, some market coverage described the outlook as mixed or flat because the range fell short of certain Street expectations. However, management raised margin and EPS targets, reflecting improved profitability despite a cautious near-term sales forecast.

The company’s Form 8-K filing confirmed the guidance figures.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI employee arrested after a hidden device was discovered; company says models identified installer and found no data loss easing investor risk.

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital convertible notes proposal would raise $850 million and include a concurrent exchange, raising dilution concerns and pressuring shares.

Character.AI Bankruptcy Draws Disney Interest

Character.AI Bankruptcy Draws Disney Interest

Character.AI bankruptcy starts a Section 363 sale with Disney as stalking-horse and $20 million bid, compressing the auction and shaping recoveries.

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile downgrade after Piper Sandler cut its target, citing launch pace doubts and SpaceX competition, tightening trader positioning.

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia incident triggered precautionary coaster closures and state reviews, raising near-term operational risk to attendance and shares.

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 earnings raised guidance to a $101.2 billion sales midpoint while MedTech weakness may force traders to reprice device risk.